Organovo Holdings, Inc., a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced a publication in the scientific journal, PLOS One, which demonstrates the superiority of Organovo’s 3D bioprinted human liver tissues to effectively model drug-induced liver injury and distinguish between highly-related compounds with different toxicity profiles. Continue reading “Research Proves Superiority of 3D Bioprinted Human Liver Tissues in Assessing Drug-Induced Toxicity”
UniQuest, the main technology transfer and commercialisation company of The University of Queensland (UQ), has signed an exclusive worldwide licensing agreement with Organovo Holdings, Inc. (NYSE MKT:ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, to patent applications relating to methodology for producing kidney cells from induced pluripotent stem cells (iPSCs).
Professor Melissa Little and her team at UQ’s Institute for Molecular Bioscience developed a method of growing kidney tissue from iPSCs for potential use in drug screening, disease modelling and cell therapy. Continue reading “Organovo Patents Methodology for Producing Kidney Cells from Induced Pluripotent Stem Cells”
Just after announcing the successful 3D printing of kidney cells, bioprinting firm Organovo has decided to add 3D printed skin to its portfolio of printable organ tissues. The company has signed a Research Collaboration Agreement with L’Oreal USA Products, Inc to 3D print skin models using their NovoGen Bioprinting Platform. Continue reading “L’Oreal Teams with Organovo to 3D Print Skin Tissue”
Every year, the pharmaceutical industry spends more than $50 billion on research and development. But the path to drug approval by the Food and Drug Administration is laden with abrupt failures in late-phase testing. One small biology company believes it has a solution to the pipeline problem: 3-D printing. Continue reading “Can 3-D Printing of Living Tissue Speed Up Drug Development?”
Organovo Holdings, Inc., a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced the full commercial release of the exVive3DTM Human Liver Tissue for preclinical drug discovery testing. Continue reading “Organovo Announces Commercial Release of the exVive3D™ Human Liver Tissue”
The global market for healthcare 3D printing is expected to reach USD 1,129.8 million by 2020, growing at an estimated CAGR of 15.6% from 2014 to 2020, according to a new study by Grand View Research, Inc. Continue reading “Global Healthcare 3D Printing Market Forecasted to Grow at CAGR of 15.6% from 2014 to 2020”
growing at an estimated CAGR of 15.6% from 2014 to 2020, according to a new study by Grand View Research, Inc.
Scientists, scientifically curious investors and Sci-Fi fanatics keep their eyes wide open on Organovo, waiting patiently for the next breakthrough of the company. Organovo developed the first commercial 3D bio-printing platform, and in 2013 the company presented data describing key features of a 3D human liver model, which is in development since then. Continue reading “Organovo and the implementation of 3D printers in BioTechnology”
A large-scale commercial application of 3D bioprinting seems now to be within reach for Organovo, the only public bioprinting company in the world, based in San Diego (CA). One of the main areas of research and development for Organovo has been the 3D reproduction — with its own bioprinters and using hydrogels as bioink — of liver tissue. Continue reading “Now It is Time to Commercially De-Liver for Organovo”
Organovo announced today that they are joining together with two institutes from the National Institutes of Health (NIH) to help scientists develop more reliable tools for bringing safer, more effective treatments to patients on a faster timeline. Organovo is collaborating with the National Center for Advancing Translational Sciences (NCATS) and the National Eye Institute (NEI) to develop better and more clinically predictive tissue models using Organovo’s NovoGen MMX Bioprinter®. Organovo will collaborate with NCATS and NEI in using the NovoGen Bioprinting platform to create three-dimensional, architecturally correct, functional living tissues. Continue reading “Organovo Announces Collaboration with National Institutes of Health”